

Supplementary Table S1. All Linear Mixed Model Effect Estimates of Treatment Group on Ocular Parameters.

Time point \ Group	Placebo	0.1% loading dose^a	0.01%^b
AL, mm			
Baseline	24.60 (24.42; 24.78)		
6-mo	24.81 (24.62; 25.00)	-0.13 (-0.16; -0.09)	-0.06 (-0.10; -0.02)
<i>p-value</i>		<0.001*	0.003*
12-mo	24.94 (24.75; 25.14)	-0.09 (-0.15; -0.04)	-0.07 (-0.13; -0.01)
<i>p-value</i>		0.002*	0.02*
18-mo	25.08 (24.87; 25.28)	-0.09 (-0.17; -0.02)	-0.09 (-0.17; -0.01)
<i>p-value</i>		0.02*	0.02*
24-mo	25.17 (24.97; 25.38)	-0.08 (-0.17; 0.01)	-0.10 (-0.19; -0.01)
<i>p-value</i>		0.08	0.02*
SER, diopters			
Baseline	-2.99 (-3.26; -2.71)		
6-mo	-3.34 (-3.65; -3.04)	0.39 (0.26; 0.53)	0.16 (0.02; 0.29)
<i>p-value</i>		<0.001*	0.03*
12-mo	-3.64 (-3.97; -3.31)	0.24 (0.09; 0.39)	0.19 (0.04; 0.34)
<i>p-value</i>		0.002*	0.01*
18-mo	-3.92 (-4.26; -3.57)	0.20 (0.01; 0.39)	0.20 (0.01; 0.40)
<i>p-value</i>		0.04*	0.04*
24-mo	-4.17 (-4.52; -3.81)	0.12 (-0.10; 0.33)	0.26 (0.04; 0.48)
<i>p-value</i>		0.30	0.02*
Distance BCVA, LogMAR			
Baseline	-0.10 (-0.12; -0.09)		
6-mo	-0.12 (-0.14; -0.10)	-0.01 (-0.03; 0.01)	0.01 (-0.01; 0.03)
<i>adjusted-p</i>		0.77	0.77
12-mo	-0.11 (-0.13; -0.10)	-0.01 (-0.03; 0.01)	-0.01 (-0.03; 0.02)
<i>adjusted-p</i>		0.71	0.85
18-mo	-0.13 (-0.15; -0.11)	0.00 (-0.02; 0.02)	0.01 (-0.01; 0.04)
<i>adjusted-p</i>		0.93	0.65
24-mo	-0.12 (-0.14; -0.10)	0.00 (-0.02; 0.02)	0.00 (-0.02; 0.02)
<i>adjusted-p</i>		0.87	0.97
Near BCVA, LogMAR			
Baseline	-0.07 (-0.09; -0.05)		
6-mo	-0.07 (-0.10; -0.05)	0.02 (0.00; 0.05)	0.01 (-0.01; 0.04)
<i>adjusted-p</i>		0.47	0.71
12-mo	-0.09 (-0.12; -0.07)	0.01 (-0.01; 0.04)	0.03 (0.00; 0.05)
<i>adjusted-p</i>		0.60	0.45
18-mo	-0.09 (-0.11; -0.06)	0.00 (-0.02; 0.03)	0.01 (-0.02; 0.04)
<i>adjusted-p</i>		0.84	0.77
24-mo	-0.08 (-0.11; -0.06)	0.00 (-0.02; 0.03)	0.01 (-0.02; 0.04)
<i>adjusted-p</i>		0.82	0.84
Accommodation amplitude, diopters			
Baseline	16.4 (15.6; 17.2)		
6-mo	14.4 (13.5; 15.4)	-4.9 (-6.0; -3.9)	-0.5 (-1.6; 0.6)
<i>adjusted-p</i>		<0.001*	0.71
12-mo	16.7 (15.7; 17.7)	-0.7 (-1.8; 0.4)	-1.1 (-2.2; 0.0)
<i>adjusted-p</i>		0.57	0.43

18-mo	16.7 (15.8; 17.7)	-0.4 (-1.5; 0.6)	0.2 (-0.9; 1.3)
<i>adjusted-p</i>		0.77	0.87
24-mo	16.8 (15.8; 17.8)	-0.5 (-1.5; 0.6)	-0.8 (-1.8; 0.3)
<i>adjusted-p</i>		0.76	0.57
IOP, mmHg			
Baseline	15.8 (15.1; 16.5)		
6-mo	16.8 (15.9; 17.7)	0.2 (-0.8; 1.3)	-0.5 (-1.6; 0.5)
<i>adjusted-p</i>		0.86	0.71
12-mo	17.3 (16.3; 18.2)	-0.1 (-1.2; 1.0)	0.2 (-0.9; 1.3)
<i>adjusted-p</i>		0.93	0.87
18-mo	17.7 (16.9; 18.6)	0.3 (-0.7; 1.3)	0.09 (-0.9; 1.1)
<i>adjusted-p</i>		0.81	0.93
24-mo	17.7 (16.7; 18.6)	0.2 (-0.9; 1.3)	-0.7 (-1.8; 0.5)
<i>adjusted-p</i>		0.87	0.67
Mesopic pupil diameter, mm			
Baseline	4.28 (4.08; 4.49)		
6-mo	4.31 (4.00; 4.62)	1.11 (0.76; 1.47)	0.19 (-0.16; 0.55)
<i>adjusted-p</i>		<0.001*	0.71
12-mo	4.31 (4.03; 4.59)	0.23 (-0.11; 0.56)	0.11 (-0.23; 0.44)
<i>adjusted-p</i>		0.57	0.80
18-mo	4.33 (4.07; 4.60)	0.12 (-0.18; 0.42)	-0.03 (-0.33; 0.27)
<i>adjusted-p</i>		0.77	0.92
24-mo	4.35 (4.10; 4.60)	-0.04 (-0.32; 0.23)	0.09 (-0.18; 0.37)
<i>adjusted-p</i>		0.87	0.80
Photopic pupil diameter, mm			
Baseline	2.80 (2.67; 2.94)		
6-mo	2.70 (2.47; 2.92)	1.04 (0.77; 1.31)	0.13 (-0.14; 0.40)
<i>adjusted-p</i>		<0.001*	0.71
12-mo	2.76 (2.58; 2.94)	0.17 (-0.05; 0.38)	0.07 (-0.14; 0.28)
<i>adjusted-p</i>		0.53	0.80
18-mo	2.74 (2.49; 2.99)	0.06 (-0.14; 0.26)	-0.06 (-0.26; 0.13)
<i>adjusted-p</i>		0.83	0.80
24-mo	2.77 (2.62; 2.91)	0.03 (-0.14; 0.19)	0.06 (-0.10; 0.23)
<i>adjusted-p</i>		0.87	0.77
Sub-foveal choroidal thickness, μm			
Baseline	242 (228; 257)		
6-mo	239 (224; 255)	13 (6; 21)	2 (-6; 10)
<i>adjusted-p</i>		0.01*	0.85
12-mo	245 (229; 261)	2 (-5; 9)	5 (-2; 13)
<i>adjusted-p</i>		0.81	0.56
18-mo	241 (225; 257)	2 (-6; 11)	4 (-5; 13)
<i>adjusted-p</i>		0.85	0.71
24-mo	242 (225; 259)	5 (-4; 14)	7 (-2; 16)
<i>adjusted-p</i>		0.68	0.49
ACD, mm			
Baseline	3.30 (3.25; 3.35)		
6-mo	3.31 (3.26; 3.37)	0.05 (0.03; 0.06)	0.02 (0.00; 0.03)
<i>adjusted-p</i>		<0.001*	0.43
12-mo	3.31 (3.26; 3.37)	0.03 (0.02; 0.05)	0.01 (0.00; 0.03)
<i>adjusted-p</i>		0.001*	0.45

18-mo	3.33 (3.28; 3.38)	0.02 (0.01; 0.04)	0.01 (0.00; 0.03)
<i>adjusted-p</i>		0.10	0.57
24-mo	3.34 (3.29; 3.39)	0.02 (0.00; 0.03)	0.02 (0.00; 0.03)
<i>adjusted-p</i>		0.40	0.40
Iridocorneal angle, degrees			
Baseline	43.9 (42.7; 45.2)		
6-mo	45.2 (43.5; 47.1)	-4.0 (-5.7; -2.2)	-1.2 (-3.0; 0.6)
<i>adjusted-p</i>		<0.001*	0.57
12-mo	45.0 (43.5; 46.5)	-1.1 (-2.6; 0.3)	-1.1 (-2.5; 0.4)
<i>adjusted-p</i>		0.53	0.56
18-mo	44.6 (43.0; 46.2)	-0.9 (-2.3; 0.4)	-0.6 (-2.0; 0.7)
<i>adjusted-p</i>		0.57	0.71
24-mo	44.9 (43.3; 46.4)	-0.5 (-1.9; 0.9)	-0.7 (-2.1; 0.7)
<i>adjusted-p</i>		0.80	0.71
CCT, μm			
Baseline	551 (545; 558)		
6-mo	554 (547; 560)	0 (-2; 2)	-2 (-4; 1)
<i>adjusted-p</i>		0.97	0.43
12-mo	554 (548; 561)	0 (-2; 2)	-2 (-4; 1)
<i>adjusted-p</i>		1.00	0.49
18-mo	553 (546; 560)	-1 (-3; 1)	1 (-2; 3)
<i>adjusted-p</i>		0.79	0.85
24-mo	553 (547; 560)	0 (-2; 2)	1 (-2; 4)
<i>adjusted-p</i>		0.90	0.77
K1 (front), diopters			
Baseline	43.03 (42.72; 43.34)		
6-mo	42.99 (42.67; 43.30)	-0.01 (-0.05; 0.03)	0.01 (-0.03; 0.05)
<i>adjusted-p</i>		0.86	0.85
12-mo	42.91 (42.60; 43.22)	0.00 (-0.04; 0.04)	0.02 (-0.03; 0.06)
<i>adjusted-p</i>		1.00	0.79
18-mo	42.86 (42.55; 43.18)	0.03 (-0.03; 0.09)	0.03 (-0.05; 0.09)
<i>adjusted-p</i>		0.71	0.71
24-mo	42.88 (42.57; 43.20)	0.04 (-0.03; 0.10)	0.00 (-0.06; 0.07)
<i>adjusted-p</i>		0.71	0.94
K2 (front), diopters			
Baseline	43.89 (43.57; 44.21)		
6-mo	43.88 (43.56; 44.21)	0.03 (-0.03; 0.09)	0.02 (-0.05; 0.08)
<i>adjusted-p</i>		0.71	0.85
12-mo	43.85 (43.52; 44.20)	0.05 (-0.01; 0.11)	0.02 (-0.03; 0.08)
<i>adjusted-p</i>		0.45	0.77
18-mo	43.84 (43.51; 44.17)	0.05 (-0.02; 0.11)	0.01 (-0.06; 0.08)
<i>adjusted-p</i>		0.57	0.87
24-mo	43.88 (43.55; 44.21)	0.06 (-0.02; 0.13)	0.00 (-0.08; 0.07)
<i>adjusted-p</i>		0.56	0.94
Lens thickness, mm			
Baseline	3.32 (3.28; 3.35)		
6-mo	3.32 (3.29; 3.36)	-0.02 (-0.04; 0.00)	-0.01 (-0.03; 0.01)
<i>adjusted-p</i>		0.16	0.57
12-mo	3.32 (3.28; 3.36)	0.00 (-0.04; 0.04)	0.00 (-0.03; 0.01)
<i>adjusted-p</i>		1.00	0.87

18-mo	3.32 (3.29; 3.36)	0.00 (-0.01; 0.02)	0.00 (-0.02; 0.01)
<i>adjusted-p</i>		0.87	0.83
24-mo	3.33 (3.29; 3.36)	-0.01 (-0.03; 0.01)	-0.02 (-0.04; 0.00)
<i>adjusted-p</i>		0.63	0.43

Effect estimates for the placebo group are total to the given time point while effect estimates for the intervention groups (0.1% loading dose and 0.01%) are differences from the placebo group at the given time point. Significance levels for exploratory secondary outcomes were reported as adj-p while primary outcomes determining treatment efficacy were excluded from FDR-adjustment and reported as p. Abbreviations: ACD, anterior chamber depth; AL, axial length; BCVA, best-corrected visual acuity; CCT, central corneal thickness; IOP, intra-ocular pressure; K1, the flat corneal meridian; K2, the steep corneal meridian; mo, months; p, p-value; adjusted-p, p-value adjusted by False Discovery Rate; SER, Spherical equivalent refraction.

^a Change in the 0.1% loading dose group compared to placebo at the given time point.

^b Change in the 0.01% group compared to placebo at the given time point.

* Statistically significant if below our p-value or adjusted-p cut-off of 0.05.